Navigation Links
Stereotaxis to Present at the Stifel Nicolaus Healthcare Conference on September 7, 2011
Date:8/25/2011

ST. LOUIS, Aug. 25, 2011 /PRNewswire/ -- Stereotaxis, Inc. (NASDAQ: STXS) today announced that executive management will present at the Stifel Nicolaus Healthcare Conference to be held September 7-9, 2011 in Boston, MA.  Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis, is scheduled to present an overview of the Company on Wednesday, September 7, 2011 at 4:25 p.m. ET.

A live webcast and subsequent archived replay of the presentation will be accessible at www.stereotaxis.com, in the "Investor Relations" section under "Events & Presentations."  

About Stereotaxis             www.stereotaxis.com         www.odysseyexperience.com

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe® Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure.

Stereotaxis' Odyssey™ portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. Odyssey™ Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey™ Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed.  Odyssey™ then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to maximize referrals and promote collaboration.

The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis to Present at the Canaccord Genuity Growth Conference on August 11, 2011
2. Stereotaxis Reports Second Quarter Financial Results; Rebalances Investment Around Commercialization of Epoch™ and Odyssey™
3. Stereotaxis to Report Second Quarter 2011 Financial Results and Conduct Conference Call on August 8, 2011
4. Stereotaxis and Biosense Webster Announce New Strategic Collaboration
5. Stereotaxis Continued Leadership in Scientific Outcome Data Prominently Displayed with Multiple Key Presentations at HRS 2011
6. Stereotaxis Reports First Quarter 2011 Financial Results
7. Stereotaxis Introduces New Electrophysiology Platform: Epoch™
8. Stereotaxis to Present at Upcoming Investor Conferences
9. Stereotaxis Reports 2010 Financial Results, Provides 2011 Financial Outlook
10. Stereotaxis Announces First Worldwide Use of Remote Magnetic Navigation for Renal Ablation to Treat Hypertension
11. Stereotaxis to Report Fourth Quarter and Full Year 2010 Financial Results and Conduct Conference Call on February 28, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... 16, 2017   The Harrington Discovery Institute ... Ohio , has announced the 2017 recipients ... discoveries of physician-scientists whose research shows promise to ... Harrington Discovery Institute – part of The Harrington ... need in academic medicine: to advance early breakthroughs ...
(Date:1/16/2017)... According to the new market research report "Display Controller Market by ... LCD Controller), Application (Industrial Control, Medical Equipment, Automotive, Mobile Communication), and Geography ... to grow from USD 17.26 Billion in 2015 to reach USD 32.24 ... Continue Reading ... ...
(Date:1/16/2017)... 2017 The report "Cellulose ... (Methyl, Ethyl, Hydroxyethyl, Hydroxypropyl, Carboxymethyl Cellulose), Application ... Coatings & Paints), Region - Global Forecast ... was valued at USD 4.51 Billion in ... 6.41 Billion by 2021, at a CAGR ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified ... Surgery Journal , the official journal of The American Society for Aesthetic Plastic ... surgery. The procedure is designed to correct drooping, retracted lower eyelids, which usually ...
(Date:1/16/2017)... , ... January 16, 2017 , ... One thing common ... to treat, but to test for, as well. The money spent screening for and ... Doctors in the U.S. screen patients for cancer more than in any other country ...
(Date:1/16/2017)... ... January 16, 2017 , ... Vixiar ... Officer of the medical device company, effective immediately. , “This is perfect timing ... has a strong track record in medical device market development and revenue growth, ...
(Date:1/15/2017)... , ... January 15, 2017 , ... In this role, ... the United States for the asthma & allergy friendly mark. This certification program was ... test and identify consumer products to be more suitable for the 60+ million people ...
(Date:1/15/2017)... ... ... Supply, LLC is announcing the release of an updated version of their top selling ... edition has wide jaws that will accommodate nails up to 4mm in thickness . ... handle is reinforced for extra strength when pressing down on dense nails which can be ...
Breaking Medicine News(10 mins):